TPST-1120 is a small molecule commercialized by Tempest Therapeutics, with a leading Phase II program in Metastatic Hepatocellular Carcinoma (HCC). According to Globaldata, it is involved in 4 clinical trials, of which 1 was completed, 1 is ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of TPST-1120’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for TPST-1120 is expected to reach an annual total of $21 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

TPST-1120 Overview

TPST-1120 is under development for the treatment of solid tumors including castration resistant prostate cancer, liposarcoma and leiomyosarcoma, cholangiocarcinoma, gastro-esophageal  cancer, head and neck cancer, hepatocellular carcinoma, non-small cell lung cancer, ovarian cancer, pancreatic  cancer, renal cell carcinoma, triple-negative breast cancer, urothelial cancer, sarcoma, MSS colorectal cancer and hematological tumor (hemonc). It is a first in class small molecule acts by targeting peroxisome proliferator activated receptor alpha (PPAR alpha). It is administered through oral route.

Tempest Therapeutics Overview

Tempest Therapeutics (Tempest), formerly Millendo Therapeutics, Inc. is a biotechnology company. It develops small molecule medicines that regulate anti-tumor immunity pathways. The company’s pipeline portfolio includes TPST-1495, an IDO (enzyme) inhibitor that generates kynurenine, a powerful immunosuppressive factor, which regulates immune cells in the tumor microenvironment (TME) and blocks anti-tumor immunity; TPST-1120, an antagonist that acts against peroxisome proliferator-activated receptor alpha (PPARa); and E-prostanoid (EP) receptor antagonists whose prostaglandin E2 (PGE2) pathway facilitates immune suppression in the TME. Tempest develops an orally available inhibitor of TREX-1 designed to activate cGAS/STING pathway, for the development of anti-tumor immunity. TempestTx is headquartered in Brisbane, California, the US.
The operating loss of the company was US$34.6 million in FY2022, compared to an operating loss of US$27 million in FY2021. The net loss of the company was US$35.7 million in FY2022, compared to a net loss of US$28.3 million in FY2021.

For a complete picture of TPST-1120’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.